Rhinovirus Infections Drug Market 2026 reaching $2.05 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Rhinovirus Infections Drug Market During 2026–2030?

The rhinovirus infections drug market size has demonstrated strong growth in recent years. It is forecasted to expand from $1.36 billion in 2025 to $1.48 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.8%. The historical growth in this market can be ascribed to the high prevalence of the common cold, the limited range of antiviral options, widespread over-the-counter drug usage, characteristic seasonal infection patterns, and consumers’ desire for quick relief.

The market for drugs treating rhinovirus infections is anticipated to experience robust expansion over the coming years. This market is projected to reach a value of $2.05 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.6%. This projected increase during the forecast period stems from progress in antiviral research, enhanced viral targeting technologies, greater public understanding of respiratory infections, the development of drugs for pediatric use, and novel approaches in nasal drug delivery. Key trends anticipated during this period encompass increased investigation into antiviral treatments for colds, an intensifying emphasis on therapies for symptom relief, the broadening of nasal spray products, a heightened appeal of immune-modulating medications, and a movement towards preventative respiratory care strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23503&type=smp

What Drivers Are Expected To Influence The Rhinovirus Infections Drug Market During The Forecast Period?

The rhinovirus infections drug market is poised for growth driven by the rising incidence of respiratory disorders. These medical conditions affect the lungs and airways, resulting in breathing difficulties, encompassing illnesses like asthma, chronic obstructive pulmonary disease (COPD), and pneumonia. This increase stems primarily from escalating air pollution and exposure to occupational hazards, contributing to a higher prevalence of conditions such as asthma, COPD, and pneumonia in affected populations. Rhinovirus infections drugs mitigate respiratory disorders by targeting viral replication, reducing inflammation, and alleviating symptoms, thereby enhancing respiratory function. A notable example is found in data from June 2025, where the Office for Health Improvement & Disparities, a UK-based government agency, reported 854,922 emergency respiratory-related hospital admissions in England for the year ending 2024. This figure, representing a rate of 1,428 per 100,000 people, marked a 7% increase from the prior year. Consequently, the rising occurrence of respiratory disorders serves as a significant impetus for the growth of the rhinovirus infections drug market.

How Are The Various Segments Of The Rhinovirus Infections Drug Market Categorized?

The rhinovirus infections drug market covered in this report is segmented –

1) By Product: Antivirals, Immunomodulators, Vaccines, Nasal Sprays, Symptomatic Treatments

2) By Patient Age Group: Infants, Children, Adults, Elderly

3) By Route Of Administration: Oral, Intranasal, Injectable

4) By Indication: Common Cold, Asthma Exacerbation, Chronic Obstructive Pulmonary Disease (COPD) Exacerbation, Other Indications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

Subsegments:

1) By Antivirals: Pleconaril, Vapendavir, Rupintrivir, Other Antivirals

2) By Immunomodulators: Interferons, Toll-Like Receptor Agonists, Other Immunomodulators

3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines

4) By Nasal Sprays: Antihistamine Nasal Sprays, Decongestant Nasal Sprays, Steroid Nasal Sprays, Saline Nasal Sprays

5) By Symptomatic Treatments: Analgesics, Antipyretics, Cough Suppressants, Expectorants, Antihistamines

What Trends Are Affecting The Expansion Of The Rhinovirus Infections Drug Market?

Key companies operating in the rhinovirus infections drug market are concentrating on creating innovative products, such as antiviral medications, to improve treatment efficacy, reduce symptom severity, and accelerate patient recovery. Antiviral drugs function by inhibiting viral replication within the body to treat viral infections. These drugs can manage various conditions including influenza, HIV, hepatitis, and rhinovirus. Their mechanisms involve either blocking virus entry into host cells or preventing viral replication and assembly. For instance, in March 2025, Altesa BioSciences Inc., a biotechnology company based in the US, received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for vapendavir, aimed at treating rhinovirus infections in individuals with COPD. Vapendavir is an oral, broad-spectrum antiviral drug designed to prevent rhinovirus from entering human cells and replicating. It has shown effectiveness against 97% of rhinoviruses and other respiratory enteroviruses. Altesa BioSciences possesses exclusive global rights for the development, manufacture, and commercialization of vapendavir. The drug’s objective is to provide targeted treatment for vulnerable groups, including those with COPD and asthma.

Which Major Firms Influence Developments In The Rhinovirus Infections Drug Market?

Major companies operating in the rhinovirus infections drug market are Pfizer Inc., Teva Pharmaceutical Industries Ltd., Cocrystal Pharma Inc., Biota Pharmaceuticals Inc., Romark Laboratories L.C., Altamira Therapeutics Ltd., Pneumagen Ltd., AIM ImmunoTech Inc., hVIVO Services Limited, Maxwell Biosciences Inc., Altesa BioSciences Inc., Via Nova Therapeutics Inc., MetP Pharma AG, Ntvirin Pharma, GlaxoSmithKline plc, Johnson & Johnson, Sanofi S.A., Bayer AG, Cipla Limited, Reckitt Benckiser Group plc

Read the full rhinovirus infections drug market report here:

https://www.thebusinessresearchcompany.com/report/rhinovirus-infections-drug-global-market-report

Which Region Is Forecast To Lead The Rhinovirus Infections Drug Market In Terms Of Market Size?

North America was the largest region in the rhinovirus infection drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rhinovirus infections drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rhinovirus Infections Drug Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23503&type=smp

Browse Through More Reports Similar to the Global Rhinovirus Infections Drug Market 2026, By The Business Research Company

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Acne Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Respiratory Syncytial Virus Rsv Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-syncytial-virus-rsv-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795